During the first few weeks of project development, the team was split into two groups so we could divide our focus between our two project ideas, L.evothyroxine and Bo-Find. Our project idea, L.evothyroxine, was based on developing a new form of drug administration for hypothyroidism. Our second project idea was Bo-Find, a detection kit for antibiotic resistance genes using loop-mediated isothermal amplification (LAMP).
To help us kickstart the initial development process, we participated in the MindFuel Tech Futures Challenge (TFC). This event is geared toward High School and University students developing projects using synthetic biology that challenge issues in the local community. Through TFC, we were also able to access resources and a mentor (Ethan Agena) who could help us along our project development. At this point in the TFC cycle, we made video pitches for both of our projects. Our hope was that we could gather enough feedback to choose which project was better suited as a focus moving forward.
During the project pitch phase, our team was awarded Best Pitch - High School for L.evothyroxine. Some of the judges’ feedback on L.evothyroxine was largely positive, though it included comments on whether our solution would be cost effective and whether this project would be feasible with our time and understanding. We also learnt that, in dealing with hypothyroidism, we must be careful, as overdosing could lead to the extreme opposite of the current issue: hyperthyroidism. This led to further ideation about possibly developing a food-activated killswitch in order to keep the thyroxine levels ideal.
The feedback on Bo-Find was equally positive, and we received suggestions on how to ensure the sustainability of our device, and regarding the next steps of development. One judge posed questions on the actions that would be necessary to actually use the device, such as how the DNA sample would be extracted from the cattle as well as how common false positives are with the use of LAMP technology. This, later on, led us to consult Dr. Tim McAllister, (as seen below) to learn more.
With feedback collected for both projects, we decided that we would choose a direction for our whole team to follow. After a team vote, we initially decided to pursue L.evothyroxine. At the time, with the research that had been done, it seemed to be the best and most interesting choice of project. However, after diving further into the subject, we discovered that overcoming the obstacle of thyroxine’s lack of solubility would prove to be very difficult, especially within the iGEM time frame. It was at this point that our team came together to decide on whether we wanted to modify the L.evothyroxine project or pivot to Bo-Find.